The Therapeutic Potential of Nanoparticles to Reduce Inflammation in Atherosclerosis

Biomolecules

Federico Carbone¹  Fabrizio Montecucco²  Amirhossein Sahebkar³  Armita Mahdavi Gorabi⁴  Nasim Kiaie⁴  Željko Reiner⁵ 

[1] First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy;IRCCS Ospedale Policlinico San Martino Genoa - Italian Cardiovascular Network, 16132 Genoa, Italy;Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran;Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran Heart Center, Tehran University of Medical Sciences, 1411713138 Tehran, Iran;University Hospital Centre Zagreb, School of Medicine University of Zagreb, Department of Internal Medicine, 1000 Zagreb, Croatia;

关键词: atherosclerosis;    cardiovascular disease;    nanoparticles;    drug delivery;    inflammation;    immune system;   

DOI  :  10.3390/biom9090416

来源: DOAJ

【 摘 要 】

Chronic inflammation is one of the main determinants of atherogenesis. The traditional medications for treatment of atherosclerosis are not very efficient in targeting atherosclerotic inflammation. Most of these drugs are non-selective, anti-inflammatory and immunosuppressive agents that have adverse effects and very limited anti-atherosclerotic effects, which limits their systemic administration. New approaches using nanoparticles have been investigated to specifically deliver therapeutic agents directly on atherosclerotic lesions. The use of drug delivery systems, such as polymeric nanoparticles, liposomes, and carbon nanotubes are attractive strategies, but some limitations exist. For instance, nanoparticles may alter the drug kinetics, based on the pathophysiological mechanisms of the diseases. In this review, we will update pathophysiological evidence for the use of nanoparticles to reduce inflammation and potentially prevent atherogenesis in different experimental models.

【 授权许可】

Unknown